ATE267583T1 - Arzneizubereitungen zur behandlung sexueller funktionsstörungen - Google Patents

Arzneizubereitungen zur behandlung sexueller funktionsstörungen

Info

Publication number
ATE267583T1
ATE267583T1 AT98912079T AT98912079T ATE267583T1 AT E267583 T1 ATE267583 T1 AT E267583T1 AT 98912079 T AT98912079 T AT 98912079T AT 98912079 T AT98912079 T AT 98912079T AT E267583 T1 ATE267583 T1 AT E267583T1
Authority
AT
Austria
Prior art keywords
treatment
medicinal preparations
functional disorders
sexual functional
sexual
Prior art date
Application number
AT98912079T
Other languages
English (en)
Inventor
Alan Drizen
Peter Rothbart
Gary M Nath
Original Assignee
Lam Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lam Pharmaceutical Corp filed Critical Lam Pharmaceutical Corp
Application granted granted Critical
Publication of ATE267583T1 publication Critical patent/ATE267583T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT98912079T 1997-03-28 1998-03-27 Arzneizubereitungen zur behandlung sexueller funktionsstörungen ATE267583T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/825,121 US5952006A (en) 1995-09-29 1997-03-28 Drug preparations for treating impotency
PCT/US1998/006020 WO1998043614A1 (en) 1997-03-28 1998-03-27 Drug preparations for treating sexual dysfunction

Publications (1)

Publication Number Publication Date
ATE267583T1 true ATE267583T1 (de) 2004-06-15

Family

ID=25243165

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98912079T ATE267583T1 (de) 1997-03-28 1998-03-27 Arzneizubereitungen zur behandlung sexueller funktionsstörungen

Country Status (11)

Country Link
US (1) US5952006A (de)
EP (1) EP0971694B1 (de)
JP (1) JP2002513410A (de)
AT (1) ATE267583T1 (de)
AU (1) AU750321B2 (de)
CA (1) CA2285181A1 (de)
DE (1) DE69824164T2 (de)
ES (1) ES2222581T3 (de)
IL (1) IL132115A0 (de)
PT (1) PT971694E (de)
WO (1) WO1998043614A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6036977A (en) * 1995-09-29 2000-03-14 L.A.M. Pharmaceutical Corp. Drug preparations for treating sexual dysfunction
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6007843A (en) * 1995-09-29 1999-12-28 Lam Pharmaceuticals Corp. Sustained release delivery system
ES2288024T3 (es) * 1998-09-04 2007-12-16 Scios Inc. Composiciones de hidrogel para la liberacion controlada en la administracion de factores de crecimiento.
KR20020015310A (ko) * 1999-04-06 2002-02-27 로버트 엘. 로브 신체적인 성적반응을 변화시키는 방법
AU5957600A (en) * 1999-07-30 2001-02-19 Lakefield Minerals Ltd. Pharmaceutical compositions for topical application to treat erectile dysfunction
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
GR1004266B (el) * 2001-04-30 2003-06-18 Ηλιας Κ. Παπαδοπουλος Φαρμακευτικο παρασκευασμα για την διαγνωση και θεραπεια της στυτικης δυσλειτουργιας
AU2004208615C1 (en) * 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
WO2004089381A1 (en) 2003-04-02 2004-10-21 Nexmed (Holdings), Inc. Prostaglandin compositions and their use for the treatment of vasospasm
US20070243632A1 (en) 2003-07-08 2007-10-18 Coller Barry S Methods for measuring platelet reactivity of patients that have received drug eluting stents
ATE536889T1 (de) * 2003-07-08 2011-12-15 Accumetrics Inc Kontrollierte thrombozyten-aktivierung zur überwachung der behandlung von adp-antagonisten
FR2877574A1 (fr) * 2004-11-08 2006-05-12 Marie Claude Benattar Utilisation d'acide hyaluronique, eventuellement en association avec au moins un androgene pour le traitement de troubles sexuels ou urinaires feminins par amplification du point g et compositions.
US8703198B2 (en) 2005-03-02 2014-04-22 Aquatrove Biosciences Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof
US20060293236A1 (en) * 2005-06-23 2006-12-28 Prescott Albert G Injectable Osteogenic Formula and Method of Using Same
TWI405580B (zh) * 2005-06-27 2013-08-21 Sankyo Co 含有血管收縮素ｉｉ接受器拮抗劑及鈣通道阻斷劑之醫藥調配物
ITMI20061030A1 (it) 2006-05-26 2007-11-27 Altergon Sa Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
GB0722507D0 (en) * 2007-11-19 2007-12-27 Zhao Xiaobin Hyaluronic acid personal lubricant
MX342511B (es) 2011-04-07 2016-10-03 Nexmed Holdings Inc Metodos y composiciones para tratar la enfermedad de raynaud.
CA2896038C (en) * 2015-07-03 2022-08-09 Glycobiosciences Inc. Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
CA1163561A (en) * 1979-11-06 1984-03-13 Cyril Boroda Preparation containing nitroglycerine and optionally other medicaments and preparation thereof
FR2542616B1 (fr) * 1983-03-17 1987-07-31 Unilever Nv Composition pour le traitement des muqueuses a base d'un antibiotique et d'un hydrocolloide formateur de gel
EP0266968A3 (de) * 1986-11-03 1988-08-24 Gérard G. Cohen Gelierte Salbe mit einem Vasodilator
US4829991A (en) * 1987-01-06 1989-05-16 Medical Engineering Corp. Method and device for stimulating an erection
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5527893A (en) * 1987-09-18 1996-06-18 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
US5017229A (en) * 1990-06-25 1991-05-21 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
IT1221826B (it) * 1988-06-08 1990-07-12 Medico Harvey Srl Centro Preparato per uso topico per il trattamento terapeutico dell impotentia coeundi
CH679670A5 (en) * 1990-10-01 1992-03-31 Applied Pharma Res Commercial carrageenan purificn. - by treatment with hydrogen peroxide in hydrated, inert organic solvent
EP0516026A1 (de) * 1991-05-28 1992-12-02 Takeda Chemical Industries, Ltd. Hydrogel und Verfahren zu seiner Herstellung
AU2300092A (en) * 1991-07-03 1993-02-11 Nathan E. Scott Prostaglandin e2 treatment of impotence
CA2071137A1 (en) * 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
WO1993012788A1 (en) * 1991-12-23 1993-07-08 The Upjohn Company Pyridylguanidine compounds for treatment of erectile dysfunction
US5646181A (en) * 1992-07-02 1997-07-08 Research Foundation Of State University Of New York Method and compositions for treating impotence
GR1002418B (el) * 1992-07-29 1996-08-21 Johnson & Johnson Consumer Products Inc. Βιοεπισυναπτομενες συνθεσεις θεραπειας και μεθοδοι χρησης.
CA2233280A1 (en) * 1995-09-29 1997-04-03 Peter Rothbart Sustained release delivery system and long acting narcotic analgesics and antagonists

Also Published As

Publication number Publication date
DE69824164D1 (de) 2004-07-01
JP2002513410A (ja) 2002-05-08
AU750321B2 (en) 2002-07-18
CA2285181A1 (en) 1998-10-08
WO1998043614A1 (en) 1998-10-08
EP0971694A1 (de) 2000-01-19
AU6588198A (en) 1998-10-22
ES2222581T3 (es) 2005-02-01
US5952006A (en) 1999-09-14
DE69824164T2 (de) 2005-07-07
IL132115A0 (en) 2001-03-19
EP0971694B1 (de) 2004-05-26
PT971694E (pt) 2004-10-29

Similar Documents

Publication Publication Date Title
ATE267583T1 (de) Arzneizubereitungen zur behandlung sexueller funktionsstörungen
BR9812134A (pt) Composição farmacêutica para tratamento de dismenorréia e parto prematuro
DE69613840D1 (de) Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle
GEP20043171B (en) Skin with a Minimal Systemic Effect
SE9703191D0 (sv) Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
BR9507506A (pt) Processo para exterminar uma célula processo para tratamento de càncer composição e kit terapéutico
DE60138547D1 (de) Topisch anwendbare arzneipräparate und verfahren zur behandlung
MX9703694A (es) Tratamiento profilactico y terapeutico de la sensibilizacion e irritacion de la piel.
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
AU4923500A (en) Device and method for increasing the transdermal permeation of medicaments
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
PT941085E (pt) Dispositivo para administracao electricamente assistida de agentes como a lidocaina e a epinefrina
UA32457C2 (uk) Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм
ATE77230T1 (de) Melatoninhaltige mittel sowie deren verwendungen.
NO984446L (no) FremgangsmÕte for behandling av smerte
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
DE69739482D1 (de) Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen
ATE384133T1 (de) Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen
RU94024337A (ru) Антиметастатическое средство
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
ATE337783T1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
NO991047D0 (no) Transdermal terapeutisk tilnµrming involverende en kombinasjon av aktive substanser inneholdende °striol
GEU2000587Y (en) Medicinal Ointment Turmanidze-Burduli Derma
RU94035330A (ru) Способ лечения кожных заболеваний

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties